STOCK TITAN

Adia Med Finds Another Unicorn

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags

Adia Med (OTCQB: ADIA) highlighted a new podcast where CEO Larry Powalisz interviews Dr. Lyday, a physician known for supporting stem cell-based treatments. Powalisz calls her a clinical "unicorn" who both researches and applies regenerative medicine.

The discussion covers stem cells, exosomes, clinical uses for conditions including Lyme disease, safety issues, and the future of regenerative medicine, aligning with Adia Med’s mission and its AdiaVita product line. The full episode is available on YouTube.

Loading...
Loading translation...

AI-generated analysis. Not financial advice.

Positive

  • None.

Negative

  • None.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CEO Larry Powalisz Spotlights Dr. Lyday, a Leading Stem Cell Champion, in New Podcast.

Winter Park, Florida--(Newsfile Corp. - June 30, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine and stem cell therapies company, today announced that CEO Larry Powalisz recently sat down for a podcast interview with Dr. Lyday, a physician recognized as a champion for stem cell-based treatments.

Cannot view this image? Visit: https://images.newsfilecorp.com/files/10520/303481_adia_550.jpg

Dr. Lyday and CEO Larry Powalisz Podcast

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/303481_adia.jpg

During the conversation, Powalisz affectionately referred to Dr. Lyday as a "unicorn" - a rare and invaluable medical professional who actively researches while wholeheartedly believing in the therapeutic potential of stem cells for improving patient outcomes.

"It's incredibly hard to find doctors who are willing to do the research and truly believe in stem cells and their benefits for their patients," said Powalisz. "Dr. Lyday is one of those unicorns. These are the physicians who see the science, embrace the possibilities, and put patients first by exploring regenerative options that conventional medicine often overlooks. We need more doctors like her."

Dr. Lyday has built a reputation as a forward-thinking advocate for stem cell and regenerative therapies, integrating innovative approaches into clinical practice to help patients with a range of conditions such as mole and Lyme disease. The podcast episode explored the science behind stem cells and exosomes, real-world clinical applications, safety considerations, and the future of regenerative medicine - topics that directly align with Adia Med's mission and its flagship AdiaVita product line.

"These unicorn doctors are essential to advancing the field," Powalisz continued. "They bridge the gap between cutting-edge research and compassionate patient care. We're proud to shine a light on Dr. Lyday's work and continue partnering with and supporting physicians who share our vision for regenerative health."

The full podcast episode featuring Larry Powalisz and Dr. Lyday is now available on YouTube at this link:



Cannot view this video? Visit:
https://www.youtube.com/watch?v=lXqdq-V6r1M

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/303481

FAQ

What did Adia Med (OTCQB: ADIA) announce on June 30, 2026?

Adia Med announced a podcast featuring CEO Larry Powalisz and Dr. Lyday discussing stem cell therapies. According to Adia Med, the episode explores science, safety, clinical applications, and future directions in regenerative medicine tied to its AdiaVita product line.

Who is Dr. Lyday in the Adia Med (ADIA) stem cell podcast?

Dr. Lyday is described as a physician championing stem cell-based treatments and regenerative therapies. According to Adia Med, she integrates innovative stem cell and exosome approaches into clinical practice for conditions including Lyme disease, aligning with the company’s regenerative health focus.

What topics are covered in the Adia Med (ADIA) podcast with Dr. Lyday?

The podcast covers stem cell and exosome science, real-world clinical applications, and safety considerations. According to Adia Med, it also looks at the future of regenerative medicine and how such therapies connect with the company’s AdiaVita product line and mission.

How does the new Adia Med (ADIA) podcast relate to the AdiaVita product line?

The podcast aligns with Adia Med’s mission and its AdiaVita flagship product line focused on regenerative medicine. According to Adia Med, discussions of stem cells, exosomes, and clinical practice reflect the same therapeutic areas as the company’s core offerings.

Where can investors watch the Adia Med (ADIA) stem cell podcast with Dr. Lyday?

Investors can watch the full podcast on YouTube via the provided link. According to Adia Med, the video features CEO Larry Powalisz and Dr. Lyday discussing regenerative medicine, patient-focused care, and the role of stem cell-based therapies in clinical practice.

Why does Adia Med’s CEO call Dr. Lyday a "unicorn" in the ADIA podcast?

CEO Larry Powalisz calls Dr. Lyday a "unicorn" for both researching and believing in stem cell therapies. According to Adia Med, he highlights her willingness to explore regenerative options that conventional medicine often overlooks while keeping patient outcomes central.